About Huateng
Our Story
Discover the journey of Huateng and our commitment to advancing medical research globally
Huateng Biopharma: Your Global Partner for Accelerated Preclinical Success
Headquartered in Guangzhou — the Silicon Valley of Asia's biotech revolution — Huateng Biopharma redefines preclinical excellence through OECD GLP-certified platforms and AAALAC-accredited translational models. Since 2019, we've become the strategic partner of choice for 300+ biopharma disruptors and MedTech pioneers across 30 countries, delivering:
☑ 85% first-cycle FDA/EMA/MDR approval rates — 35% higher than industry average
☑ 40% cost reduction via AI-driven study design and Asia-EU parallel testing
☑ 6-month faster timelines for Class III implants & orphan drug development
Core Capabilities
1. Next-Gen Drug Development
IND/IDE Acceleration: Mechanistic MOA validation → GLP tox packages
Smart ADME/PK-PD: AI-powered PBPK modeling & microdosing predictions
Global Compliance: ICH-aligned protocols for US/EU/APAC submissions
2. Medical Device Breakthroughs
Surgical Mastery: 95% success rate in porcine/canine/NHP models (ECMO, artificial hearts)
MDR 2024-Ready: Full Annex XIV testing (ISO 10993 biocompatibility, cybersecurity)
Digital Twins: VR-enhanced device implantation simulations
3. Translational Edge
CRISPR-Edited Models: 200+ disease-specific large animal platforms
Biomarker Hunting: ML-driven discovery with 92% clinical correlation
Path to Partnership
Path to Partnership Consult:Free regulatory roadmap session (60 mins)
Design:AI-optimized protocol in 72h
Execute:Real-time dashboards & milestone alerts
Submit:Globally compliant reports
Our Journey
Key milestones in Huateng's history of innovation and growth/p>
The company was registered
Received angel round investment from Huachongde Fund
Establish subsidiary Guangdong Mingzhu
Changzhou Island CRO real laboratory opened Selected national enterprises in the Innovation and Entrepreneurship Competition Complete the first IND application to the National Medical Products Administration
Obtained pre-A round investment from Zhenhua Fund
Establish subsidiary shengzheng huateng Recognized as a national high-tech enterprise
Won the A round of funding from Fofo Guangdong and Create
Set up subsidiary Chongqing Jiten Science City Lab Opens CRO Project Management System Goes Live Complete the first three kinds of medical device animal experiment data submitted to the National Medical Products Administration for approval
Received investment from Yang and Investment and Wanlian Securities in A+ round
Establishment of Jiangsu Wanwei subsidiary Establish a biosafety laboratory
Received B round funding from Tianhe Fund
Subsidiary Jiangsu Wanwei obtained experimental animal production license
Our Core Values
The principles that guide our work and define our culture
Scientific Excellence
We are committed to maintaining the highest standards of scientific rigor and excellence in all our research and services, ensuring reliable and reproducible results.
Global Collaboration
We believe in the power of collaboration across borders and disciplines to drive innovation and advance medical research for the benefit of people worldwide.
Innovation
We continuously seek innovative approaches and technologies to improve our services and contribute to advancements in medical research and healthcare.
Integrity
We conduct our business with the highest level of integrity, transparency, and ethical standards, building trust with our clients, partners, and the scientific community.
Client Focus
We are dedicated to understanding and meeting the unique needs of our clients, providing personalized service and support throughout their research journey.
Continuous Improvement
We are committed to continuously improving our processes, services, and capabilities to deliver greater value to our clients and advance medical research.